DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

HMS (Medrysone Ophthalmic) - Summary

 
 



HMS SUMMARY

HMS®
(medrysone ophthalmic suspension) 1%

HMS® (medrysone ophthalmic suspension) 1% is a topical anti-inflammatory agent for ophthalmic use.

HMS® (medrysone ophthalmic suspension) is indicated for the treatment of allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity.


See all HMS indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to HMS (Medrysone Ophthalmic)

Biorhythms
Source: MedicineNet Allergic Cascade Specialty [2016.08.17]
Title: Biorhythms
Category: Diseases and Conditions
Created: 9/30/1998 12:00:00 AM
Last Editorial Review: 8/17/2016 12:00:00 AM

Abnormal Heart Rhythms (Heart Rhythm Disorders)
Source: MedicineNet Wolff-Parkinson-White Syndrome Specialty [2016.02.18]
Title: Abnormal Heart Rhythms (Heart Rhythm Disorders)
Category: Diseases and Conditions
Created: 10/15/2007 12:00:00 AM
Last Editorial Review: 2/18/2016 12:00:00 AM

Resetting Body Clock May Help the Brain to Heal (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2017.04.21]
(MedPage Today) -- Circadian temperature rhythms linked to arousal in study

more news >>

Published Studies Related to HMS (Medrysone Ophthalmic)

Predicting hospitalization due to worsening heart failure using daily weight measurement: analysis of the Trans-European Network-Home-Care Management System (TEN-HMS) study. [2009.04]
CONCLUSION: A MACD algorithm is more specific but less sensitive than RoT when trying to predict episodes of WHF based on daily weight measurements. However, many episodes of WHF do not appear to be associated with weight gain and therefore telemonitoring of weight alone may not have great value for heart failure management.

Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. [2005.05.17]
OBJECTIVES: We sought to identify whether home telemonitoring (HTM) improves outcomes compared with nurse telephone support (NTS) and usual care (UC) for patients with heart failure who are at high risk of hospitalization or death. BACKGROUND: Heart failure is associated with a high rate of hospitalization and poor prognosis. Telemonitoring could help implement and maintain effective therapy and detect worsening heart failure and its cause promptly to prevent medical crises... CONCLUSIONS: Further investigation and refinement of the application of HTM are warranted because it may be a valuable role for the management of selected patients with heart failure.

Identifying patients at risk of death or hospitalisation due to worsening heart failure using decision tree analysis: Evidence from the Trans-European Network-Home-Care Management System (TEN-HMS) Study. [2011.07.02]
OBJECTIVES: To stratify patients recently discharged from hospital with heart failure (HF) according to their risk of death and/or hospitalisation for worsening HF (WHF), to enable timely and appropriate monitoring and intervention... CONCLUSIONS: Decision trees are an alternative classification method used to differentiate risk in patients with HF. The resultant models are concise, free of subjective variables and understood easily by clinicians. Further exploration of their potential and validation in other data-sets is justified. Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.

Hyper reactive malarial splenomegaly (HMS). [2006.07]
Hyper reactive malarial splenomegaly (HMS) is a relatively rare chronic complication of malaria. Previous name of the disease was Tropical splenomegaly syndrome (TSS).The boy was discharged with malaria prophylaxis for a long time & advised to come to our unit every month for further follow up.

more studies >>

Clinical Trials Related to HMS (Medrysone Ophthalmic)

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers [Completed]
The objectives of this study is to determine the safety profiles, tolerability, pharmacokinetics and pharmacodynamics of HMS5552 following single ascending doses in healthy adult subjects.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes [Completed]
The objectives of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of HMS5552 following multiple ascending doses in patients with type 2 diabetes mellitus.

Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting [Recruiting]
This is a feasibility study of an artificial pancreas (AP) system with our previously validated Zone-MPC and Health Monitoring System (HMS) algorithms (ClinicalTraisl. gov: NCT01929798) integrated into the Diabetes Assistant (DiAs) system.

Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients [Completed]
This study evaluates the beta cell function, pharmacodynamics, pharmacokinetics, safety and tolerability after 4 weeks treatment of 75mgBID or 75mgQD of HMS5552.

Hämeenlinna Metabolic Syndrome Research Program: Oxidized LDL and Arterial Elasticity in Metabolic Syndrome and Controls (HMS-01) [Completed]
Mechanisms that link metabolic syndrome to atherosclerosis are incompletely understood. As a part of Hämeenlinna Metabolic Syndrome Research Program (HMS), 40 men with metabolic syndrome and their 40 physically active controls (age: 30 to 65 years) are compared in a cross-sectional study. Except routine laboratory parameters, arterial elasticity and levels of oxidized LDL are determined. Study hypothesis: Levels of oxidized LDL and findings in arterial elasticity may differ between subjects with metabolic syndrome and controls explaining the elevated risk for cardiovascular diseases among patients with metabolic syndrome.

more trials >>


Page last updated: 2017-04-21

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017